Status Of Ranbaxy’s First Filer Status For Dioxan Remains A Mystery After Judge Tosses Mylan Lawsuit
This article was originally published in PharmAsia News
Executive Summary
Court says U.S. FDA handled changed USP monograph appropriately, but ruling sheds no new light on the status of first-filer Ranbaxy’s tentatively approved valsartan ANDA or when the first generic version of Novartis’ single-ingredient anti-hypertensive agent will enter the market.
You may also be interested in...
Mylan vs. FDA (And Ranbaxy): Diovan Exclusivity Forfeiture Edition
In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.
At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion
Agency’s presentations on Biogen/Ionis’ ALS drug included differing viewpoints from the statistical and clinical pharmacology teams; the transparency and emphasis on a multidisciplinary review approach may reflect lessons learned from missteps at the Aduhelm panel review in 2020.
BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review
A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.